Axsome Therapeutics, Inc.
AXSM
Rang in Aktien
#2402
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Aktienkurs
$156.05
Marktkapitalisierung
$8.17B
Veränderung (1 Tag)
-0.70%
Veränderung (1 Jahr)
21.97%
Land
US
Handel Axsome Therapeutics, Inc. (AXSM)
Kategorie
Healthcare
Operative Marge für Axsome Therapeutics, Inc. (AXSM)
Operative Marge zum October 2026 TTM: -24.28%
Laut den neuesten Finanzberichten und dem Aktienkurs von Axsome Therapeutics, Inc. beträgt die aktuelle operative Marge (TTM) -24.28%. Am Ende des Jahres 2023 lag die operative Marge bei -85.67%.
Historie der operativen Marge von Axsome Therapeutics, Inc. von 2013 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -24.28% | -66.62% |
| 2024 | -72.74% | -15.09% |
| 2023 | -85.67% | -75.71% |
| 2022 | -352.74% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -101.59% |
US
|
|
| -149.01% | -93.86% |
US
|
|
| 25.57% | -101.05% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -101.19% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.